BamSEC and AlphaSense Join Forces
Learn More

Poseida Therapeutics Inc.

NASDAQ: PSTX    
Share price (12/20/24): $9.45    
Market cap (12/20/24): $921 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 12 pages Form of Tender and Support Agreement
12/34/56
EX-10.1
from 10-Q 9 pages Third Amendment to the Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 94 pages Collaboration and License Agreement Between Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. April 30, 2024
12/34/56
EX-10.6
from 10-Q 4 pages Second Amendment to the Collaboration and License Agreement
12/34/56
EX-10.5
from 10-Q 7 pages Docusign Envelope Id: B9ce0636-Cd27-4ab6-A535-A599d6b572bf March 15, 2024 Syed Rizvi, M.D. Delivered via Docusign Re: Offer of Employment 1
12/34/56
EX-10.1
from 10-Q 5 pages Poseida Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: July 1, 2020 Effective: July 9, 2020 Amended and Restated: July 23, 2021 Amended and Restated: May 24, 2022 Amended and Restated: September 7, 2023 Amended and Restated: November 27, 2023
12/34/56
EX-10.30
from 10-K 12 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. First Amendment to the Collaboration and License Agreement
12/34/56
EX-10.3
from 8-K 7 pages Second Amended and Restated Executive Employment Agreement
12/34/56
EX-10.2
from 8-K 4 pages Poseida Therapeutics, Inc. Severance and Change in Control Plan Amended and Restated Participation Agreement
12/34/56
EX-10.1
from 8-K 9 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Poseida Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: July 1, 2020 Effective: July 9, 2020 Amended and Restated: July 23, 2021 Amended and Restated: May 24, 2022 Amended and Restated: September 7, 2023
12/34/56
EX-10.3
from 8-K 9 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 29 pages Securities Purchase Agreement
12/34/56
EX-10
from 10-Q 6 pages February 22, 2023 Kristin Yarema Delivered via Email Re: Offer of Employment 1
12/34/56
EX-10
from 10-K 8 pages January 6, 2022 Brent Warner Delivered via Email Re: Offer of Employment Dear Brent
12/34/56
EX-10
from 10-K 5 pages July 1, 2020 Harry Leonhardt Delivered via Email Re: Offer of Employment Dear Harry
12/34/56
EX-10
from 10-K 11 pages February 1, 2023 Eric M. Ostertag, M.D., PH.D. Re: Transition and Consulting Agreement Dear Eric: This Letter Sets Forth the Substance of the Transition and Consulting Agreement (The “Agreement”) That Poseida Therapeutics, Inc. (The “Company”) Is Offering to You in Connection With Your Employment Transition. 1
12/34/56
EX-10
from 10-K 11 pages Poseida Therapeutics, Inc. Rsu Award Grant Notice – NON-U.S
12/34/56
EX-10
from 10-K 16 pages Poseida Therapeutics, Inc. Stock Option Grant Notice – NON-U.S
12/34/56